UPDATE: Prima Biomed Receives A$475,000 in Grant Funding from EU, German Free State of Saxony
Prima BioMed Ltd (NASDAQ: PBMD) is pleased to announce that it has received approximately €306,000 (A$475,000) in grant funding from the European Union and the German Free State of Saxony. The gr ant, administered by the Sächsische AufbauBank (the Saxony Development Bank), relates to the past development work on the CVac™ therapy.
Since 2010 Prima has been collaborating on CVac with the Fraunhofer Institute of Cell Therapy and Immunology, a leading European cell therapy research centre located in Leipzig, supported by the Saxony Development Bank. This is the final tranche of funding to be received by Prima for CVac from this grant program.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.